StreetInsider.com News Articles

BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Tue, 08 Sep 2026 13:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - BioVaxys Technology Corp. (OTC Pink: BVAXF) (CSE: BIOV) (FSE: 5LB), ("BioVaxys" or the "Company") a clinical-stage biopharmaceutical company focused on the development of durable, single-dose, vaccines for safe, scalable, and long-lasting immune protection in oncology, infectious disease, and immune dysfunctions, is pleased to announce its participation at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. James Passin, Chief Executive Officer, will be attending the conference, delivering an investor presentation and participating in scheduled 1-on-1 meetings with investors.

Date: Wednesday,

BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Tue, 08 Sep 2026 13:30:00 -0400

Date: Wednesday,

BioVersys begins Phase 3 trial for antibiotic targeting resistant bacteria

Thu, 16 Apr 2026 01:00:20 -0400

BioVersys AG (SIX: BIOV) announced the first patient enrollment in its Phase 3 clinical trial for BV100, an experimental antibiotic designed to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii.

The RIV-TARGET trial aims to enroll approximately 300 patients across 100 sites in 15 countries. The study will compare BV100 combined with low-dose polymyxin B against a combination of colistin and high-dose ampicillin-sulbactam in patients with suspected or confirmed infections from carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex.

The trial follows a Phase 2 study that showed a 50% reduction in mortality compared with standard therapy. In that earlier study, 28-day mortality

BioVersys begins Phase 3 trial for antibiotic targeting resistant bacteria

Thu, 16 Apr 2026 01:00:20 -0400

The trial follows a Phase 2 study that showed a 50% reduction in mortality compared with standard therapy. In that earlier study, 28-day mortality

BioVersys begins Phase 3 trial for antibiotic targeting resistant bacteria

Thu, 16 Apr 2026 01:00:20 -0400

The trial follows a Phase 2 study that showed a 50% reduction in mortality compared with standard therapy. In that earlier study, 28-day mortality

BioVersys begins Phase 3 trial for antibiotic targeting resistant bacteria

Thu, 16 Apr 2026 01:00:20 -0400

The trial follows a Phase 2 study that showed a 50% reduction in mortality compared with standard therapy. In that earlier study, 28-day mortality

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Thu, 16 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) --

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.
Global pivotal Phase 3 trial is

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Thu, 16 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) --

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.
Global pivotal Phase 3 trial is

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Thu, 16 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) --

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.
Global pivotal Phase 3 trial is

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Thu, 16 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) --

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.
Global pivotal Phase 3 trial is

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Thu, 16 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) --

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.
Global pivotal Phase 3 trial is

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Thu, 16 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) --

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.
Global pivotal Phase 3 trial is

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Thu, 16 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) --

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.
Global pivotal Phase 3 trial is

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Thu, 16 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) --

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.
Global pivotal Phase 3 trial is

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Wed, 15 Apr 2026 01:00:00 -0400

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) --

Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
ESCMID is the premier annual congress of the European Society of Clinical Microbiology